PDE9A Promotes Calcium-Handling Dysfunction in Right Heart Failure via cGMP-PKG Pathway Suppression: A Mechanistic...

Area of Science:

• Cardiovascular Research
• Molecular Cardiology
• Pharmacology

Background:

• Right heart failure (RHF) is a significant cause of illness and death, often linked to pulmonary arterial hypertension.
• Impaired calcium handling and maladaptive remodeling are hallmarks of RHF.
• Phosphodiesterase 9A (PDE9A) may contribute to RHF by inhibiting the cardioprotective cGMP-PKG pathway.

Purpose of the Study:

• To review the role of PDE9A in the pathogenesis of RHF.
• To examine PDE9A's effects on calcium cycling, fibrosis, hypertrophy, and contractile dysfunction in RHF.
• To evaluate PDE9A inhibition as a potential therapeutic strategy for RHF.

Main Methods:

• Review of preclinical data on PDE9A expression and function in RHF models.
• Analysis of studies investigating the effects of pharmacological and genetic PDE9A inhibition.
• Examination of early-phase clinical trial data for PDE9A inhibitors in heart failure populations.

Main Results:

• Pathological stress increases PDE9A in RHF cardiomyocytes, impairing cGMP-PKG signaling, SERCA2a function, and increasing calcium leak.
• PDE9A inhibition restores cGMP signaling, improves calcium handling, and reduces cardiac remodeling and dysfunction.
• Early clinical studies show PDE9A inhibitors are safe and increase cGMP levels.

Conclusions:

• PDE9A plays a critical role in RHF by disrupting calcium handling and promoting adverse remodeling.
• Targeting PDE9A offers a promising therapeutic avenue for RHF by addressing underlying molecular mechanisms.
• Further clinical trials are needed to confirm the efficacy of PDE9A inhibitors specifically in RHF.